Lifeward LTD 8-K filings

Lifeward Ltd. has expanded its Board of Directors to eight members with the appointment of Mark Grant, while current Co-CEO Larry Jasinski will resign from the Board, as the company sets its Annual General Meeting for August 1, 2025.

Lifeward Ltd. announced that Chief Financial Officer Michael Lawless will resign effective June 27, 2025, citing personal reasons and no disagreements with the company's financial practices.

Lifeward Ltd. has appointed Mark Grant as its new President and CEO, effective June 2, 2025, to drive growth and profitability.

Lifeward Ltd. reports a slight revenue decrease year-over-year for Q1 2025, but highlights progress in ReWalk adoption, AlterG growth, and improved operating expense management.

Lifeward Ltd. announces the U.S. national launch of the ReWalk 7 Personal Exoskeleton, featuring new and improved functionalities for individuals with spinal cord injury.

Lifeward Ltd. reports preliminary Q1 2025 revenue of approximately $5.0 million and the departure of its Chief Sales Officer, Charles Remsberg, effective May 30, 2025.

Lifeward Ltd. has entered into an agreement with H.C. Wainwright & Co., LLC to offer and sell up to $5.48 million of its ordinary shares through an at-the-market offering.

Lifeward Ltd. reports record quarterly and annual revenue, driven by strong growth in U.S. ReWalk opportunities and a strategic shift towards profitability with its 2025 Sustainable Growth Plan.

Lifeward Ltd. reports preliminary 2024 revenue of $25.7 million and announces the departure of CEO Larry Jasinski by the end of Q2 2025.

Lifeward Ltd. has cancelled its Extraordinary General Meeting of Shareholders scheduled for January 13, 2025, and withdrawn the proposals that were to be considered.

Lifeward Ltd. has filed an amendment to its original 8-K report to correct errors in the exhibits related to ordinary and placement agent warrants.

Lifeward Ltd. has entered into a definitive agreement for a $5 million registered direct offering of ordinary shares and warrants.

Lifeward Ltd. reported a 39% increase in revenue for the third quarter of 2024, driven by strong sales of ReWalk systems and the launch of the AlterG NEO.

Lifeward Ltd. has expanded its Board of Directors from six to seven members, appointing Robert J. Marshall Jr. as a Class III director and chair of the Audit Committee, effective November 2, 2024.

ReWalk Robotics held its 2024 Annual Meeting of Shareholders, approving a name change to Lifeward Ltd. and electing two Class I directors, while other proposals did not receive sufficient support.

Lifeward's Q2 2024 revenue surged over 400% year-over-year to $6.7 million, fueled by Medicare reimbursements and strong sales of ReWalk systems.

ReWalk Robotics' Board Chair, Jeff Dykan, will retire at the 2024 Annual General Meeting, with Joseph Turk appointed as his successor.

Lifeward's Q1 2024 revenue soared by 340% year-over-year to $5.3 million, fueled by the newly established Medicare payment for personal exoskeletons.

Lifeward (ReWalk Robotics Ltd.) has appointed Mike Swinford, a seasoned healthcare executive, to its Board of Directors, effective April 18, 2024.

ReWalk Robotics has regained compliance with Nasdaq's minimum bid price requirement after its share price remained above $1.00 for ten consecutive business days.

ReWalk Robotics is leveraging recent Medicare coverage and strategic acquisitions to expand its reach in the rehabilitation technology market.

Lifeward, formerly ReWalk Robotics, reported record annual revenue of $13.9 million for 2023 and completed its operational integration, expecting $3 million in annual savings.

ReWalk Robotics has rebranded as Lifeward, effective January 29, 2024, and will trade under the new ticker symbol LFWD starting January 30, 2024.